Clinical Trials Directory

Trials / Conditions / Advanced Tumors

Advanced Tumors

21 registered clinical trials studyying Advanced Tumors — 6 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
NCT07205198
Shanghai Institute Of Biological ProductsPhase 1
RecruitingDose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
NCT07110584
ModeX Therapeutics, An OPKO Health CompanyPhase 1 / Phase 2
RecruitingTarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
NCT06788938
Jonsson Comprehensive Cancer CenterPhase 2
RecruitingA Study of CS23546 in Subjects With Advanced Tumors
NCT06245122
Chipscreen Biosciences, Ltd.Phase 1
RecruitingIndividualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)
NCT06314087
The University of Hong Kong-Shenzhen HospitalPhase 2
TerminatedA SHR-1210 BE Study on Healthy Subjects
NCT05799183
Jiangsu HengRui Medicine Co., Ltd.Phase 1
CompletedA Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
NCT05429008
HutchmedPhase 1
UnknownA Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in
NCT05390528
Shanghai Henlius BiotechPhase 1 / Phase 2
UnknownA Study of PM1022 in Patients With Advanced Tumors
NCT05867771
Biotheus Inc.Phase 1 / Phase 2
UnknownClinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advance
NCT05213767
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Phase 1
TerminatedA Study of HRS2543 in Patients With Advanced Tumors
NCT05068856
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 1
CompletedPhase I Study of CPI-300 in Patients With Advanced Tumors
NCT04808453
Coordination Pharmaceuticals, Inc.Phase 1
UnknownThe Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalim
NCT05061628
Shanghai Junshi Bioscience Co., Ltd.Phase 1
RecruitingA Study of AL58805 in Patients With Advanced Tumors
NCT07179081
Advenchen Laboratories Nanjing Ltd.Phase 1
TerminatedA Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
NCT04198818
Haihe Biopharma Co., Ltd.Phase 1 / Phase 2
CompletedPhase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
NCT04151810
Dragonboat Biopharmaceutical Company LimitedPhase 1
UnknownPhase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
NCT03908814
Dragonboat Biopharmaceutical Company LimitedPhase 1
CompletedPlatform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1
NCT03697304
Boehringer IngelheimPhase 2
CompletedStudy of CPI-100 in Patients With Advanced Tumors
NCT03781362
Coordination Pharmaceuticals, Inc.Phase 1
CompletedPhase I Study of RiMO-301 With Radiation in Advanced Tumors
NCT03444714
Coordination Pharmaceuticals, Inc.Phase 1
CompletedStudy of BMS-986158 in Subjects With Select Advanced Cancers
NCT02419417
Bristol-Myers SquibbPhase 1 / Phase 2